---
title: "Rising Flu Trends in Autumn and Winter Create a Window of Urgent Demand for Anti-Flu Products at YSB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305889599.md"
description: "Since November, flu activity has continued to rise, driving sales growth of cold medications in out-of-hospital channels. As an out-of-hospital pharmaceutical distribution platform, YSB connects upstream pharmaceutical companies with hundreds of thousands of downstream grassroots pharmacies. Leveraging its advantages of 460,000 monthly active buyers and 4.3 million SKUs, it is well-positioned to meet procurement demands, entering a window of opportunity for urgent anti-flu product needs"
datetime: "2026-11-18T00:31:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305889599.md)
  - [en](https://longbridge.com/en/news/305889599.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305889599.md)
generator: "portal-rs"
---

# Rising Flu Trends in Autumn and Winter Create a Window of Urgent Demand for Anti-Flu Products at YSB

Zhitong Finance APP learned that since November, flu activity has continued to rise. According to the weekly influenza surveillance report from the Chinese Center for Disease Control and Prevention, there were 145 reported outbreaks of influenza-like illnesses nationwide during the 43rd week (October 19–25), approximately 5.2 times the 28 outbreaks reported in the previous week. By the 45th week, the positivity rate for influenza-like illness samples in outpatient and emergency departments rose from 14.7% to 18.8%. Southern provinces are experiencing moderate epidemic levels, while northern provinces remain at low epidemic levels but show a recent upward trend.

The earlier onset of the flu season has transmitted to out-of-hospital channels. Data from Zhongkang shows that the national pharmacy sales index for viral cold medications increased by 7.28 points and 15.89 points week-on-week during the 43rd and 44th weeks, respectively. The daily average sales per store increased by 3.6% and 5.7% week-on-week, respectively, which is lower than the 25.1% and 54.9% increases seen in the same period of 2025.

At the category level, cold medications showed a turning point in the third quarter. Zhongkang data indicates that year-on-year retail sales for cold/heat-clearing, cough-suppressing/phlegm-resolving/asthma-relieving, and oral/throat products shifted from declines of 27.6%, 18.5%, and 6.8% in the first quarter to growth of 11.7%, 7.8%, and 5.0% in the third quarter, totaling approximately RMB 47.4 billion for the first three quarters. During the same period, the average transaction value per store dropped to RMB 64, a 4% year-on-year decrease, with no concentrated stockpiling observed at the terminal level.

Although consumers have not engaged in concentrated stockpiling, the pressure of inventory preparation falls on pharmacies. Zhongkang data shows that the average number of orders for cold medications per pharmacy in the third quarter was 184 orders per store per month, ranking first among all categories and serving as a key traffic driver for grassroots pharmacies. Stocking up for the flu season tests the supply stability and replenishment speed of common medications. Out-of-hospital pharmaceutical distribution platforms represented by YSB (09885) operate in this segment, connecting upstream pharmaceutical companies and distributors with downstream services for hundreds of thousands of grassroots pharmacies and clinics. They fulfill procurement demands through both proprietary trading and platform channels. The interim report shows that the platform has approximately 460,000 monthly active buyers and about 4.3 million monthly salable SKUs.

From an industry perspective, the total number of pharmacies is decreasing, making single-store efficiency the focus of operations. Whether the supply side can stably provide high-margin categories and maintain compliance capabilities directly affects the operational space of individual stores. Analysts believe that the incremental demand in this flu season is concentrated in antiviral chemical drugs, pathogen testing, and pediatric formulations. Platforms with strong category organization capabilities are better positioned to capture this demand. Based on a net profit attributable to shareholders of RMB 153 million in 2025, YSB's current market capitalization is approximately HKD 2.1 billion, corresponding to a P/E ratio of about 14 times. The actual intensity and duration of the flu season remain variables determining the height of demand and warrant close attention.

### Related Stocks

- [09885.HK](https://longbridge.com/en/quote/09885.HK.md)

## Related News & Research

- [YSB Files Next-Day Disclosure Return to HKEX on Share Buyback for Cancellation](https://longbridge.com/en/news/306092399.md)
- [YSB Files Next-Day Disclosure With HKEX Announcing Share Buyback for Cancellation](https://longbridge.com/en/news/306246349.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Nearly 1 In 5 Tesla Model Ys Failed Their First German Inspection](https://longbridge.com/en/news/306107102.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**